ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,242Medicare Part D Prescriptions Filled, Including Refills

Rank: 215 out of 2456

$499K Total Retail Price of All Prescriptions

Rank: 233 out of 2456

420 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

21% of this provider’s 420 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

9% of this provider’s 420 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 7,178 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
SIMVASTATIN 499 413 1 2
LISINOPRIL 464 371 2 1
AMLODIPINE BESYLATE 368 338 3 5
OMEPRAZOLE 276 203 4 3
FUROSEMIDE 269 206 5 8
ATENOLOL 226 172 6 6
HYDROCHLOROTHIAZIDE 225 217 7 7
METOPROLOL TARTRATE 193 179 8 10
LEVOTHYROXINE SODIUM 190 155 9 4
WARFARIN SODIUM 186 176 10 9
METOPROLOL SUCCINATE 175 146 11 13
PRAVASTATIN SODIUM 153 109 12 15
ATORVASTATIN CALCIUM 149 144 13 12
HYDROCODONE-ACETAMINOPHEN 145 100 S3 14 20
LOSARTAN POTASSIUM 140 125 15 18
CITALOPRAM HBR 136 92 16 14
ZOLPIDEM TARTRATE 120 70 17 28
OXYCODONE HCL 115 68 S2 18 38
OXYCODONE-ACETAMINOPHEN 108 41 S2 19 35
PROAIR HFA 107 79 20 22
RANITIDINE HCL 104 68 21 31
METFORMIN HCL ER 99 66 22 59
CRESTOR 95 86 23 25
CYMBALTA 89 69 24 65
GABAPENTIN 84 47 25 16
PREDNISONE 81 69 26 39
DIGOXIN 81 75 26 49
ZETIA 80 68 28 86
IBUPROFEN 78 33 29 52
METFORMIN HCL 72 64 30 11
PAROXETINE HCL 70 70 31 56
KLOR-CON M20 69 46 32 69
AZITHROMYCIN 66 51 33 60
CIPROFLOXACIN HCL 66 57 33 87
OXYCODONE HCL-ACETAMINOPHEN 65 30 S2 35 101
NIFEDIPINE ER 64 48 36 61
TRAMADOL HCL 64 49 36 24
PANTOPRAZOLE SODIUM 59 48 38 37
GLYBURIDE 58 49 R 39 40
VERAPAMIL ER 58 33 39 91
SPIRIVA 53 46 41 43
ALENDRONATE SODIUM 52 52 42 19
FLUTICASONE PROPIONATE 51 27 43 30
SERTRALINE HCL 50 47 44 21
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 27, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.